Richard Kinh Gian Do, MD, PhD
Radiologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Director, Research, Body Imaging Service and Director, Hepatobiliary Radiology
I am a radiologist who specializes in body imaging, with expertise in imaging for liver cancer, bile duct cancer, and pancreatic cancer. I help oncologists make the best decisions possible for treating people with these hepatopancreatobiliary (HPB) cancers.
From diagnosis and staging to treatment response, I am committed to delivering accurate and actionable reports for the care of people with cancer. I have practiced at Memorial Sloan Kettering Cancer Center (MSK) for more than a decade, and my goal is to continuously improve the diagnosis and treatment of cancer through active research.
Read more
My research interests include advanced computed tomography (CT) and magnetic resonance imaging (MRI) techniques for HPB tumors. I also work with computer scientists to investigate the potential applications of computer-based medical image analysis and text analysis in this area. Computer-based image analysis lets us look at medical images beyond what the human eye can see. Medical images contain a vast amount of hidden data. We are harnessing this big data to predict tumor pathology, genetics, and response to treatment. With computer-based text analysis (also called natural language processing), we can identify trends in disease patterns and response from thousands of patients at a time. These analyses provide insight into how cancers metastasize over time.
In addition to research, I am active in the American College of Radiology. Together with other radiologists, I have developed new guidelines for treatment response assessment for hepatocellular carcinoma and other liver tumors. I frequently lecture on HPB tumors at meetings for the Radiological Society of North America and the Society of Abdominal Radiology. Finally, as Chair of the MSK Radiology Reporting Committee, I lead a team of radiologists to ensure that our clinical reports are as clear as possible so that our patients and clinicians can make the best treatment decisions.
A radiologist is a doctor with special training in using imaging to diagnose and treat disease. Imaging includes X-rays, computed tomography (CT), and magnetic resonance imaging (MRI).
My Specialties
- Abdominal Radiology
Education
- MD, Weill Cornell Medical College
- PhD, Weill Cornell Graduate School of Medical Sciences
Residencies
- NYU Langone Medical Center
Fellowships
- NYU Langone Medical Center
Board Certifications
- Diagnostic Radiology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, HMO
MSK has a tentative agreement with Cigna to continue coverage in 2024.
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Do sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Do
- The Prevention of Progression to Pancreatic Cancer Trial (The 3PC Trial)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Do RKG, Lefkowitz RA, Hatzoglou V, Ma W, Juluru K, Mayerhoefer M. Standardized Reporting of Oncologic Response: Making Every Report Count. Radiol Imaging Cancer. 2022 Jun;4(4):e220042. doi:10.1148/rycan.220042. PMID: 35657292; PMCID: PMC9358481.
Do RKG, Lupton K, Causa Andrieu PI, Luthra A, Taya M, Batch K, Nguyen H, Rahurkar P, Gazit L, Nicholas K, Fong CJ, Gangai N, Schultz N, Zulkernine F, Sevilimedu V, Juluru K, Simpson A, Hricak H. Patterns of Metastatic Disease in Patients with Cancer Derived from Natural Language Processing of Structured CT Radiology Reports over a 10-Year Period. Radiology. 2021 Oct;301(1):115-122. doi: 10.1148/radiol.2021210043. Epub 2021 Aug 3. PMID: 34342503; PMCID: PMC8474969.
Read more
Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018 Dec;289(3):816-830. doi:10.1148/radiol.2018181494. Epub 2018 Sep 25. PMID: 30251931; PMCID: PMC6677371.
Creasy JM, Midya A, Chakraborty J, Adams LB, Gomes C, Gonen M, Seastedt KP, Sutton EJ, Cercek A, Kemeny NE, Shia J, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D’Angelica MI, Do RKG, Simpson AL. Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. Eur Radiol. 2019 Jan;29(1):458-467. doi:10.1007/s00330-018-5542-8. Epub 2018 Jun 19. PMID: 29922934; PMCID: PMC6301122.
Patient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Richard Kinh Gian Do discloses the following relationships and financial interests:
-
Ascelia Pharma AB
Professional Services and Activities -
Elsevier
Intellectual Property Rights
-
International Diagnostic Course Davos (IDKD)
Professional Services and Activities -
The Royal Australian and New Zealand College of Radiologists (RANZCR)
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
